| ||||||
| ||||||
|
Learn
|
Learn |
|||||
Novel Therapies (Artemisinin/Gardasil)After learning of their diagnosis, many patients try a variety of alternative methods. (1) Holistic aproaches: Since stress is never good for the immune system, it can be said that stress-reduction is, in general, a good thing. It doesn't really lead to lengthy remissions, however, unless there was overwhelming stress in the beginning, and even here, it is unrealistic to expect that interventions like chiropractic manipulations or even energy work (massage, acupuncture, etc.) will do much for most patients on any kind of long term basis with respect to HPV/RRP. Alternative approaches also include taking a variety of vitamins, herbs (e.g., echinacea) or homeopathic remedies (e.g. thuja). None of these can be said to offer significant benefit with respect to RRP, however. The serum (blood borne) immune system isn't what's lacking in the RRP patient. It's the local immune system, and here naturopathic and homeopathic remedies seem pretty ineffective. Exercise is necessary for health, but this too isn't a viable approach in dealing with RRP. (2) Gardasil and Artemisinin: It is uncertain whether the use of Gardasil and/or artemisinin can in fact be properly called "alternative," but this approach appeared to induce long term remission in this writer. It also seemed to have dramatically helped other patients who have reported in as well. For more on this topic, please see the articles below and the material in the sub-menus.
Artemisinin Dr. Richard Schlegel, at Georgetown University, had been using artemisinin and artemisinin-like compounds. for some years. He reported on this at the 2005 RRP Focus Session meeting sponsored by RRP ISA. Dr. Schlegel's work had been done on dogs, which were adopted out after being put into remission following treatment, where artemisinin was painted on their vocal cords. This was after they had been infected with a canine version of RRP, and after they expressed symptoms. Long story short, the administrator of this website took a system dose, described in Novel Therapies> Guidelines. Others have done so too, as described in Novel Therapies>Patient Reports. HPV tumors express transferrin receptors. Some experts at the University of Washington think that these receptors are designed to take the iron that freely circulates in the blood (a ferric form), converting it into the ferrous form, used inside cells. Now, ART isn't supposed to affect the "inactive" form of iron in the blood or the stomach, but it superoxidizes the ferrous form inside the cell. University of Washington experts have suggested that it subsequently deprives the HPV of its food source. It also engenders cell death through a process called apoptosis in HPV-infected cells, but appears to do virtually nothing to normal cells. It does much the same thing in cancer cells but there, we're not talking about a virus but a malignancy. The question arises: Is this an intervention that the research and medical communities needs to take seriously? It would be presumptuous for this writer to try and answer that question. The University of Washington thinks it does. Dr. Schelegel at Georgetown University thinks it does. Dr. Tom Broker (the molecular biologist at the Universitty of Alabama) thinks it does. Many other people do as well. Consider an essential bibliography of ART research published by the University of Washington's School of Bioengineering. Artemisinin for cancer treatment has gained a lot of momentum recently. 14 papers were published in the first three months of 2009. 1.) http://www.uwnews.org/article.asp?articleID=44335 Oct. 13, 2008 | The new compound puts a novel twist on the common anti-malarial drug artemisinin, which is derived from the sweet wormwood plant (Artemisia annua L). Sweet wormwood has been used in herbal Chinese medicine for at least 2,000 years, and is eaten in salads in some Asian countries. Researchers at the University of Washington have updated a traditional Chinese medicine to create a compound that is more than 1,200 times more specific in killing certain kinds of cancer cells than currently available drugs, heralding the possibility of a more effective chemotherapy drug with minimal side effects.
3.) There is new research about the anti-viral properties of artemisinin and artesunate at a research center in Germany. The abstract and the link to the abstract on pubmed are included below. http://www.ncbi.nlm.nih.gov/pubmed/18699744?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum 4.) Artemsinin abstracts and URLS 5.) Cancer smart bomb. Very informative: 6.) Calcium and survivin are involved in the induction of apoptosis by dihydroartemisinin in human lung cancer SPC-A-1 cells. www.ncbi.nlm.nih.gov/entrez/query.fcgi
7.) Artesunate in the treatment of metastatic uveal melanoma--first experiences. 10.) From the University of Washington - this appears to be pretty current as it lists publications related to effects of aArtemisinin and its analogs on Cancer many of which are dated 2007. 13.) Very nice summary on ART in 2003, as offered in a Gulf Coast Veterinary Oncology bulletin. This was an application that was years ahead of its time. One confusion exists here, when the author seems to momentarily confuse the terms "artemisinin and artemether." The latter is neurotoxic in animals if they ingest high qualities. While artemether is derived from artemisinin, it is not artemisinin. We know of no such neurotoxic reports associated with artemisinin or artesunate.
Dr. Richard Schlegel is highly respected HPV researcher who is currently working under a Bill and Melinda Gates Foundation grant. In the 2007 RRP Focus Session presentation, he explained his research in using L1 VLP vaccine, similar to Gardasil. Dr. Schlegel's presentation was quite detailed, showing that a vaccine like Gardasil was powerfully therapeutic. He noted that immunoglobulins are irrelevant to therapy. He strongly supported RRP ISA's research proposal to study Gardasil and artemisinin in tandem (this is NOT interlesional Gardasil to which we refer--this is not a "Dr. Strangelove/MMR redux protocol"--but use of Gardasil in a standard immunization protocol). In private discussion with RRP ISA, Dr. Ian Frazer, the noted Australian immunologist who can claim many of the patent rights on Gardasil, said that VLPs like Gardasil may indeed exert a therapeutic effect on RRP. Indeed, he indicated his RRP therapeutic vaccine currently being tested (2007) was very much like Gardasil, but without the alum adjuvant. It should be noted that Merck's conclusion that Gardasil doesn't work therapeutically is based ONLY on cervical and genital data. We believe that generalizing zero therapeutic efficacy from cervical data is simply bad science. On the RRP ISA message board (March 28, 2008), Dr. Bettie Steinberg--a molecular biologist who is a respected expert on RRP and HPV--made the following observation. She wrote:
RRP ISA has long said that there is good reason to conclude that the respiratory tract behaves differently from the genital tract (see argument referring to RRP epidemiology amongst AIDS patients in RRP ISA's 2007 RRP Focus Session material). Merck's own medical staff have privately admitted they do not know what Gardasil (or other VLPs) will do or not do in the respiratory tract. They haven't ever tested for efficacy outside the genital region. It is quite possible that the Gardasil potentiates the body's ability to "see" the foreign HPV invader and acts synergistically with artemisinin and artesunate, which in turn acts as a potent (HPV-specific) cytotoxic agent. The following excerpt from an email sent to RRP ISA adds further credibility to our speculations. Dr. Richard Schlegel has given us permission to publish it here., From: Richard Schlegel
|
||||||
